



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/042,226	01/11/2002	Bernd Riedl	BAYER 25A	5076
23599	7590	09/14/2005	EXAMINER	
MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			JONES, DWAYNE C	
		ART UNIT	PAPER NUMBER	1614

DATE MAILED: 09/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/042,226	RIEDL ET AL.	
	Examiner Dwayne C. Jones	Art Unit 1614	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 24JUN2005.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) See Continuation Sheet is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 6,7,9-11,13,15,38,39,44-49,53,54,66,67,70,71,73,75,76,78,80,81,83 and 88-121 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/09)
Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: _____

DETAILED ACTION***Status of Claims***

1. Claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 are pending.
2. Claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 are rejected.

Response to Arguments

3. Applicants' arguments filed June 24, 2005 have been fully considered but they are not persuasive. Applicants present the following arguments. First, applicants maintain that all pending claims clearly comply with the written description requirement of 35 USC 112, first paragraph. Second, applicants attempt to maintain their broad claims by showing state of the art publications, namely Kolch et al. and Monia et al., to show that one skilled in the art would clearly understand the scope of the terms used in defining the conditions to be treated with the compounds of the invention. Third, applicants even argue that the teachings of Monia et al. state that "These studies strongly suggest that antisense inhibitors targeted against the C-raf kinase may be of considerable value in antineoplastic agents that display activity against a wide spectrum of tumor types at well-tolerated dosages." Fourth, applicants submit that the specification does provide guidance on how to prepare pharmaceutical compositions and in treating any and all cancers encompassed by the instant claims. Fifth, applicants also submit that there is no requirement that an applicant provide any working examples relating to the treatment of every claimed disease to satisfy the statute.

4. First, applicants maintain that all pending claims clearly comply with the written description requirement of 35 USC 112, first paragraph. In particular, applicants submit that the compounds of Formula I are now adequately described because the phrase "substituted moiety of up to 40 carbon atoms" does not appear in any of the instant claims. However, the rejection of record stated that "the instant claims are *replete* with phrases such as 'carbon based moiety of up to 24 carbon atoms optionally containing one or more heteroatoms' or even 'substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure' for the variables of R_y and B, respectively. Moreover, these phrases are not adequately described for the variables of R_z, R_x, R_f, R_a, R_b, W, Z. Another example of the not adequately described phrases is with respect to variable M, which is defined as 'a bridging group having at least one atom.' (Emphasis added). Accordingly, the rejection provided examples not an exhaustive list of the many examples of the inadequately described variables of R_z, R_x, R_f, R_a, R_b, W, Z and M. For instance, there is a lack of written description for every aryl moiety as well as every possible hetaryl and cycloalkyl and cycloalkyl groups with heteroatoms in the instant specification.

5. Second, applicants attempt to maintain their broad claims by showing state of the art publications, namely Kolch et al. and Monia et al., to show that one skilled in the art would clearly understand the scope of the terms used in defining the conditions to be treated with the compounds of the invention. But as stated in the previous Office Action, one skilled in the art would use the Kolch et al. only teach and only adequately describe the compounds in that Raf-1 protein function was c-raf-1 antisense RNA or

kinase-defective c-raf-1 mutants, while the prior art reference of Monia et al. only describe that phosphorothioate antisense oligodeoxynucleotides inhibit C-raf-1 kinase. These alleged prior art reference fail to support the teachings of the instant specification by showing that the instantly described compounds are effective in the treatment of cancerous cell growth mediated by RAF kinase as well as the treatment of all solid cancers (like claim 71) directed to carcinomas, myeloid disorders or adenomas.

6. Third, applicants even argue that the teachings of Monia et al. state that "These studies strongly suggest that antisense inhibitors targeted against the C-raf kinase may be of considerable value in antineoplastic agents that display activity against a wide spectrum of tumor types at well-tolerated dosages." However, this quote only indicates to one skilled in the art that more undue experimentation is required, as evidenced by the use of the word "suggest" by Monia et al. Accordingly, this argument is not found persuasive.

7. Fourth, applicants submit that the specification does provide guidance on how to prepare pharmaceutical compositions and in treating any and all cancers encompassed by the instant claims. Due to the unpredictability of the cancer art, the lack of direction and guidance with the use of immensely broad compound as that of claimed Formula (I), such as with respect to the broad terms that are embraced by variables of R_z, R_x, R_f, R_a, R_b, W, Z and M as well as only providing the in vitro treatment of two tumor cell lines of HCT 116 and DLD-1 to support treating all carcinomas, myeloid disorders or adenomas.

8. Fifth, applicants also submit that there is no requirement that an applicant provide any working examples relating to the treatment of every claimed disease to satisfy the statute. But when the absence of working examples are combined with other Wands factors, such as the breadth of the claims, the lack of guidance and direction, the predictability of the efficacy of chemotherapeutic agents in the field of the cancer art, the level of the skilled artisan and the complex nature of chemotherapeutics and oncology, the instant claims not enabled for the alleged entire scope of all for the treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf.

Claim Rejections - 35 USC § 112

9. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

10. The rejection of claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is maintained for both the above stated and reasons of record. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

11. There is a lack of written description in the specification, as well as the instant claims for the various types of variables that are embraced by the compound of Formula (I). The claimed methods of treatment fail meet the requirement for an adequate written description of the claimed invention as required by 35 U.S.C. 112, first paragraph. In addition, the instant specification does not describe what is meant by the phrase the various definitions for the variables of A, B, R_y, R_z, R_x. For example, the variable of A, for instance with the phrase "substituted moiety of up to 40 carbon atoms . . . "

12. Claims 1-3, 6, 8, 10-13, 15, 17-19, 21, 27, 28, 32, 33, 37-39, 43-50, 52-54, and 66-89 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

13. There is insufficient descriptive support for the phrase treatment of cancerous cell growth mediated by RAF kinase as well as the treatment of solid cancers and the treatment of carcinomas, myeloid disorders or adenomas. The claimed methods of treatment fail meet the requirement for an adequate written description of the claimed invention as required by 35 U.S.C. 112, first paragraph. In addition, the instant specification does not describe what is meant by the phrase treatment of cancerous cell growth mediated by RAF kinase as well as the treatment of solid cancers and the treatment of carcinomas, myeloid disorders or adenomas. Structural identifying characteristics of the phrase treatment of cancerous cell growth mediated by RAF

kinase as well as the treatment of solid cancers and the treatment of carcinomas, myeloid disorders or adenomas. There is no evidence that there is any per se structure/function relationship between the phrase treatment of cancerous cell growth mediated by RAF kinase as well as the treatment of solid cancers and the treatment of carcinomas, myeloid disorders or adenomas. The instant specification does provide an adequate written description for the phrase treatment of cancerous cell growth mediated by RAF kinase as well as the treatment of solid cancers and the treatment of carcinomas, myeloid disorders or adenomas. In the absence of some understanding of the conditions to be treated one of ordinary skill in the art would not have concluded that Applicant was in possession of the claimed methods. Accordingly, these claims fail to comply with the written description requirement.

14. The rejection of claims 7, 9 and 90-121 under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement is maintained for both the above stated and reasons of record. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

15. There is insufficient descriptive support for the phrase the treatment of a raf mediated disorder. The claimed methods of treatment fail meet the requirement for an adequate written description of the claimed invention as required by 35 U.S.C. 112, first paragraph. The claimed methods require treatment of an unspecified disease or disorder and no evidence indicates that a treatable disease was known to Applicants.

In addition, the instant specification does not describe what is meant by the phrase the treatment of a raf mediated disorder. Structural identifying characteristics of the phrase the treatment of a raf mediated disorder There is no evidence that there is any per se structure/function relationship between the phrase the treatment of a raf mediated disorder. The instant specification does provide an adequate written description for the phrase the treatment of a raf mediated disorder. In the absence of some understanding of the conditions to be treated one of ordinary skill in the art would not have concluded that Applicant was in possession of the claimed methods. Accordingly, these claims fail to comply with the written description requirement.

16. *Regents of the University of California v. Eli Lilly & Co., 119 F.3d 1559, 1568 (Fed. Cir. 1997), cert. denied, 523 U.S. 1089, 118 S.Ct. 1548 (1980)*, holds that an adequate written description requires a precise definition, such as by structure, formula, chemical name, or physical properties, "not a mere wish or plan for obtaining the claimed chemical invention." *Eli Lilly*, 119 F.3d at 1566. The Federal Circuit has adopted the standard set forth in the Patent and Trademark Office ("PTO") Guidelines for *Examination of Patent Applications Under the 35 U.S.C. 112, 1 "Written Description" Requirement* ("Guidelines"), 66 Fed. Reg. 1099 (Jan. 5, 2001), which state that the written description requirement can be met by "showing that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics, "including, inter alia, "functional characteristics when coupled with a known or disclosed correlation between function and structure...." *Enzo Biochem, Inc. v. Gen-Probe., 296 F.3d, 316, 1324-25 (Fed. Cir. 2002)* (quoting Guidelines, 66 Fed. Reg. At 1106 (emphasis added)).

Moreover, although *Eli Lilly* and *Enzo* were decided within the factual context of DNA sequences, this does not preclude extending the reasoning of those cases to chemical structures in general. *Univ. of Rochester v. G.D. Searle & Co.*, 249 F. Supp.2d 216, 225 (W.D.N.Y 2003).

17. Claims 1-3, 6-13, 15, 17-19, 21, 27, 28, 32, 33, 37-39, 43-50, 52-54, and 66-121 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the *in vitro* treatment of the tumor cell lines of HCT116 and DLD-1, does not reasonably provide enablement for the treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Among these factors are: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and (8) the quantity of experimentation necessary. When the above factors are weighed, it is the examiner's position that one skilled in the art could not practice the invention without undue experimentation.

(1) The nature of the invention:

The instant invention is directed to the treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf. The method comprises administering the compounds of Formula (I).

(2) The state of the prior art

The compounds of the inventions are compounds of Formula (I). However, the prior art teaches that there are many types of cancers and various causative agents that involve different cellular mechanisms, and, for thus, differ in treatment protocol, see Stein, J. H.

(3) The relative skill of those in the art

The relative skill of those in the art of cancer pharmaceuticals is high.

(4) The predictability or unpredictability of the art

The unpredictability of the pharmaceutical art is very high. In fact, the courts have made a distinction between mechanical elements function the same in different circumstances, yielding predictable results, chemical and biological compounds often react unpredictably under different circumstances. Nationwide Chem. Corp. v. Wright, 458 F. Supp. 828, 839, 192 USPQ 95, 105(M.D. Fla. 1976); Aff'd 584 F.2d 714, 200 USPQ 257 (5th Cir. 1978); In re Fischer, 427 F.2d 833, 839, 166 USPQ 10, 24 (CCPA 1970). Thus, the physiological activity of a chemical or biological compound is

considered to be an unpredictable art. For example, in Ex Parte Sudilovsky, the Court held that Appellant's invention directed to a method for preventing or treating a disease known as tardive dyskinesia using an angiotensin converting enzyme inhibitor involved unpredictable art because it concerned the pharmaceutical activity of the compound. 21 USPQ2d 1702, 1704-5 (BDAI 1991); In re Fisher, 427 F.2d 1557, 1562, 29 USPQ, 22 (holding that the physiological activity of compositions of adrenocorticotropic hormones was unpredictable art); In re Wright, 999 F.2d 1557, 1562, 29 USPQ d, 1570, 1513-14 (Fed. Cir. 1993) (holding that the physiological activity of RNA viruses was unpredictable art); Ex Parte Hitzeman, 9 USPQ2d 1821, 1823 (BDAI 1987); Ex Parte Singh, 17 USPQ2d 1714, 1715, 1716 (BPAI 1990). Likewise, the physiological or pharmaceutical activity of the urea-containing compounds prior to filing of the instant invention was an unpredictable art.

(5) The breadth of the claims

The instant claims are very broad. For instance, claim 6 is directed to the plethora of compounds of Formula (I) and for treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf. The breadth of claims was a factor in Amgen v. Chugai Pharm. Co., 927 F.2d 1200, 18 USPQ2d (Fed. Cir.), cert. Denied, 502 U.S. 856 (1991). In the Amgen case, the patent claims were directed to DNA sequences that encoded amino acid sequences. Because a very small change in the amino acid sequence of a protein can result in a very large change in the structure-function activity of a protein and

because the laws of protein folding are in such a primitive state, predicting protein structure (and hence, activity) while knowing only the sequence of the protein is akin to predicting the weather for a date in the future.

(6) The amount of direction or guidance presented

The amount of guidance or direction needed to enable the invention is inversely related to the degree of predictability in the art. In re Fisher, 839, 166 USPQ 24. Thus, although a single embodiment may provide broad enablement in cases involving predictable factors, such as mechanical or electrical elements, in cases involving unpredictable factors, such as most chemical reactions and physiological activity, more teaching or guidance is required. In re Fischer, 427 F.2d 839, 166 USPQ 24; Ex Parte Hitzeman, 9 USPQ 2d 1823. For example, the Federal Circuit determined that, given the unpredictability of the physiological activity of RNA viruses, a specification requires more than a general description and a single embodiment to provide an enabling disclosure for a method of protecting an organism against RNA viruses. In re Wright, 999 F.2d 1562-63, 27 USPQ2d 1575. In the instant case, given the unpredictability of the physiological or pharmaceutical activity of a Formula (I) to be effective in treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf is insufficient for enablement. The specification provides no guidance, in the way of enablement for treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells other than the *in vitro* treatment of the tumor cell lines of HCT116 and DLD-1. In re

Fisher, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 27 USPQ2d 1510 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one species, what other species will work. In re Dreshfield, 110 F.2d 235, 45 USPQ 36 (CCPA 1940), gives this general rule: "It is well settled that in cases involving chemicals and chemical compounds, which differ radically in their properties it must appear in an applicant's specification either by the enumeration of a sufficient number of the members of a group or by other appropriate language, that the chemicals or chemical combinations included in the claims are capable of accomplishing the desired result." The article "Broader than the Disclosure in Chemical Cases," 31 J.P.O.S. 5, by Samuel S. Levin covers this subject in detail. A disclosure should contain representative examples, which provide reasonable assurance to one skilled in the art that the compounds fall within the scope of a claim will possess the alleged activity. See In re Riat et al. (CCPA 1964) 327 F2d 685, 140 USPQ 471; In re Barr et al. (CCPA 1971) 444 F 2d 349, 151 USPQ 724.

(7) The presence or absence of working examples

As stated above, the specification discloses the compounds of Formula (I) that have the ability of treating of all types of cancers, solid cancers, carcinomas, myeloid disorders, adenoma, and cancerous cells, and disorders mediated by raf.. However, the

instant specification only has enablement for the *in vitro* treatment of the tumor cell lines of HCT116 and DLD-1.

(8) The quantity of experimentation necessary

The quantity of experimentation needed to be performed by one skilled in the art is yet another factor involved in determining whether "undue experimentation" is required to make and use the instant invention. "The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed." In re Wands, 858 F.2d 737, 8 USPQ2d 1404 (citing In re Angstadt, 537 F.2d 489, 502-04, 190 USPQ 214, 218 (CCPA 1976)). For these reasons, one of ordinary skill in the art would be burdened with undue "painstaking experimentation study" to determine all of the generic group of compounds of Formula I that are used in that would be enabled in this specification.

18. The rejection of claims 1, 10, 33, 68, 69, 74, 79, and 84 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn.

19. The rejection of claim 113 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn in response to the amendment of June 24, 2005.

Obviousness-type Double Patenting

20. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

21. The provisional rejection of claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 62-67 are of copending Application No. 09/948,915 is maintained. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are directed to the treatment of cancerous cell growth with urea containing compounds.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

22. The provisional rejection of claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 29, 30, 32, and 33 of copending Application No. 09/777,920 is maintained. Although the conflicting

claims are not identical, they are not patentably distinct from each other because to the treatment of cancerous cell growth with urea containing compounds.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

23. The provisional rejection of claims 6, 7, 9-11, 13, 15, 38-39, 44-49, 53-54, 66, 67, 70, 71, 73, 75, 76, 78, 80, 81, 83, and 88-121 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-81; 15-19; 62-67; 67; 26-29 and 35-38; 74-98; 74, 80, 81, 87, 93, 99, 110-121; 1, 18-20; 24-26; 62-67; 14, 16-19, 21-27; 1, 19, 20, 25-30; 74-98; 1-26, 30-40, 45-49; 1-32; 1 and 40-58; 1, 14, 23-38; 1, 14-23; 1, 9-18; and 18-24 of copending Application Nos. 09/640,780; 09/776,936; 09/907,970; 09/889,227; 09/472,233; 09/993,647; 10/042,203; 10/071,248; 10/125,369; 10/283,248; 10/361,850; 10/895,985; .09/993,647; 10/361, 844; 10/361,858; 10/788,029; 10/788,405; 10/788,426; 10/789,446; 09/750,060, respectively between each set of semicolons. Although the conflicting claims are not identical, they are not patentably distinct from each other because to the treatment of cancerous cell growth with urea containing compounds.

24. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

1. **THIS ACTION IS MADE FINAL.** Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (571) 272-0578. The examiner can normally be reached on Mondays, Tuesdays, Wednesdays, and Fridays from 8:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, may be reached at (571) 272-0951. The official fax No. for correspondence is (571)-273-8300.

Also, please note that U.S. patents and U.S. patent application publications are no longer supplied with Office actions. Accordingly, the cited U.S. patents and patent application publications are available for download via the Office's PAIR, see <http://pair-direct.uspto.gov>. As an alternate source, all U.S. patents and patent application publications are available on the USPTO web site (www.uspto.gov), from the Office of Public Records and from commercial sources.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications may be obtained from Private PAIR only. For more information about PAIR system, see <http://pair-direct.uspto.gov> Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 1-866-217-9197 (toll free).

Dwayne Jones
DWAYNE JONES
PRIMARY EXAMINER
Tech. Ctr. 1614
September 9, 2005

Continuation of Disposition of Claims: Claims pending in the application are 6,7,9-11,13,15,38,39,44-49,53,54,66,67,70,71,73,75,76,78,80,81,83 and 88-121.